Latest Kaiser Health News Stories
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
Kaiser Health News reporter Shefali Luthra discusses the controversy surrounding Kaleo, a company that makes a life-saving auto-injector for opioid drug overdoses on Weekend Edition.
Wood, who chairs the Assembly Health Committee, lays out his priorities for 2017.
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
Follow the twists and turns of the orphan drug industry over the past three decades.
Check out all the drugs the FDA has approved to treat rare diseases. You can search by brand name, or by disease, and see familiar names that were first sold on the mass market or all the drugs that won FDA approval to treat more than one rare disease.
The former Congressman championed the Orphan Drug Act decades ago but now he fears it’s being manipulated to make money.
The federal government pays for kidney transplants. But the program only pays for essential anti-rejection drugs for three years. Many people can’t afford them and can end up losing the kidney.
Investigators claim drugmaker employees met in secret at restaurants, golf outings and at “Girls Night Out” to raise generic drug prices.
Eight percent of those polled by the Kaiser Family Foundation say they have purchased medications outside of the U.S. to save money.
Advocates want alternatives to drugmaker’s pricey pills for those who choose to die in Colorado and elsewhere.
Three lobbyists for every member of Congress in a push to pass a bill that increases research funding and speeds up approvals.
The legislation would give federal officials more flexibility in evaluating the effectiveness and safety of drugs and devices and add billions of dollars to NIH funding. But critics say it could endanger patients’ safety and doesn’t do enough to stop spiraling drug prices.
Despite heavy opposition from the pharmaceutical industry and skepticism from policy experts, many voters see Proposition 61 as a way to protest the nation’s mounting drug prices.
Majorities of Democrats, Republicans and independents support making sure high-cost drugs for chronic conditions are affordable.
Climbing drug prices are taking a toll on West Virginia’s budget, some state legislators say. Expensive drugs fuel an increase in Medicaid spending, which leaves less money for schools and roads.
The plans sought to discourage costly HIV patients by not including their drug needs in formularies or requiring high cost sharing, a Harvard Law School group says in a complaint filed with HHS.
In a report out Tuesday, hospital groups said drug prices have skyrocketed since 2013, triggering a huge increase in what hospitals spend on pharmaceuticals.